Replies to post #125850 on Biotech Values

[DewDiligence]

If Teva isn't in a dealing mood, how to you model the chances of Sandoz launching [Copaxone] at-risk?

I expect NVS/MNTA to launch at risk if they think they have a 55% or better chance of ultimately prevailing in the litigation. It requires slightly better than 50:50 odds to justify launching because the monetary damages in the worst-case scenario* would be apt to slightly exceed the monetary benefits in the best-case scenario.

*Excluding the unlikely outcome of treble damages.